SIU 2017: En-Bloc Transurethral Resection of Non muscle invasive Bladder Cancer: Pathological Effectiveness
Lisbon, Portugal (UroToday.com) En-bloc transurethral resection (en-bloc TUR) is a modified procedure of transurethral resection of the bladder tumor (TURBT) for the patients with non-muscle invasive bladder cancer. The authors of this study investigated cases of en-bloc TUR and the pathological effectiveness in diagnosis.
SIU 2017: The Synergic Effect of Metformin and Everolimus in Renal Cell Carcinoma
Lisbon, Portugal (UroToday.com) This study investigated the anti tumor effect of metformin combined with everolimus on renal cell carcinoma cell lines.
SIU 2017: Survival Outcomes of Younger Men (55 Years) Undergoing Radical Prostatectomy
Lisbon, Portugal (UroToday.com) While prostate cancer is typically a disease of older men, with prevalence increases with each decade of life, it can and does occur in younger men. As these men are younger, treatment options are usually more easily accessible and more options are available. However, quality of life also plays an important role.
SIU 2017: Maximal Preservation of Intra-Pelvic Urethra Using Suture-Less Technique to Improve Early Continence after Radical Prostatectomy: 15 Years Experience
Lisbon, Portugal (UroToday.com) Urinary continence after radical prostatectomy is an important quality of life indicator. As men, particularly younger men, undergo radical treatment for cancer, urinary continence is just as important for most as cancer control. As such, many attempts have been made to help improve continence outcomes.
SIU 2017: Cytoreductive and Palliative Radical Prostatectomy, Lymphadenectomy and Bilateral Orchiectomy in Advanced Prostate Cancer with Oligo-And Polymetastases
Lisbon Portugal (UroToday.com) The authors aimed to show the role of radical prostatectomy, lymphadenectomy and bilateral orchiectomy instead of androgen deprivation therapy (ADT) as an alternative treatment in patients with advanced prostate cancer with oligo-and bone poly-metastases.
SIU 2017: MP15 – 04- Polymer Delivered, Subcutaneously Administered Leuprolide Acetate Achieves Effective Testosterone Suppression below Castration Levels
Lisbon, Portugal (UroToday.com) Polymer-delivered, subcutaneous leuprolide acetate (SC-LA) has previously been shown to suppress serum testosterone (T) levels in prostate cancer patients. Luteinizing hormone-releasing hormone agonists are currently dosed independently of body weight (BW) or age. Due to the importance of achieving low T during androgen deprivation therapy, the authors attempted to understand whether patient specific factors such as age or weight may need to be taken into consideration when choosing therapy. The objective was to determine if patient weight and age correlates with the pharmacodynamic profile of SC-LA in pivotal trials of all currently available formulations (1,3,4, and 6-month doses).
SIU 2017: MP15 – 03- EMT And CD133 Expression of Circulating Tumor Cell in Predicting Prognosis and Docetaxel-Based Treatment Effect in Metastatic Castration-Resistant Pro State Cancer
Lisbon, Portugal (UroToday.com) Although circulating tumor cell (CTC) enumeration in peripheral blood has already been validated as a reliable biomarker in predicting prognosis in metastatic castration-resistant prostate cancer (mCRPC), patients with favorable CTC counts (CTC < 5/7.5 ml) still experience various survival times.
In this study, the authors attempted to explore EMT and CD133 expression of CTCs in predicting prognosis and treatment effect in mCRPC.